PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Alembic Pharmaceuticals Limited (APLLTD.NS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISININE901L01018
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Highlights

Market Cap₹175.22B
EPS (TTM)₹31.34
PE Ratio28.43
Total Revenue (TTM)₹62.29B
Gross Profit (TTM)₹40.42B
EBITDA (TTM)₹9.57B
Year Range₹593.94 - ₹1,094.00
Target Price₹927.36

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Alembic Pharmaceuticals Limited

Performance

Performance Chart

The chart shows the growth of an initial investment of ₹10,000 in Alembic Pharmaceuticals Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


500.00%1,000.00%1,500.00%2,000.00%2,500.00%2024FebruaryMarchAprilMayJune
2,124.82%
685.57%
APLLTD.NS (Alembic Pharmaceuticals Limited)
Benchmark (^GSPC)

S&P 500

Returns By Period

Alembic Pharmaceuticals Limited had a return of 16.96% year-to-date (YTD) and 45.82% in the last 12 months. Over the past 10 years, Alembic Pharmaceuticals Limited had an annualized return of 13.94%, outperforming the S&P 500 benchmark which had an annualized return of 10.77%.


PeriodReturnBenchmark
Year-To-Date16.96%13.87%
1 month-8.43%2.54%
6 months15.77%15.10%
1 year45.82%23.18%
5 years (annualized)14.20%13.48%
10 years (annualized)13.94%10.77%

Monthly Returns

The table below presents the monthly returns of APLLTD.NS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202426.48%6.16%-3.42%1.50%-7.65%16.96%
2023-6.05%-5.01%-2.92%12.05%-1.73%16.44%23.03%0.30%1.00%-9.10%4.59%1.82%34.02%
2022-5.63%-4.16%2.25%5.33%-6.29%-0.51%-3.60%-6.24%-6.72%-9.02%8.09%-3.65%-27.46%
2021-7.84%-3.35%4.80%2.15%-3.51%3.48%-18.83%-4.57%5.02%-1.51%3.80%-0.60%-21.29%
202010.40%-0.12%-14.75%39.17%17.17%4.78%7.92%-4.36%-0.43%2.83%3.47%3.57%81.90%
2019-1.01%-6.52%-6.14%6.98%-7.03%-1.80%4.07%-4.96%2.31%7.98%0.34%3.52%-3.73%
20186.88%-2.53%-0.80%-2.61%-19.95%17.57%12.24%7.11%4.90%-5.10%3.44%-2.87%13.90%
2017-5.86%3.53%8.18%-2.41%-12.31%-5.73%5.60%-2.09%-2.53%-0.28%2.56%2.50%-10.14%
2016-11.29%0.10%-3.18%0.69%-11.61%7.75%10.14%0.14%4.18%3.14%-1.99%-10.09%-13.91%
20155.60%-12.62%10.68%4.12%16.63%20.09%7.60%0.68%-4.38%-0.69%2.04%0.48%57.08%
20145.40%20.36%6.44%4.54%-17.28%8.01%31.94%6.64%11.68%-1.23%2.78%5.79%112.84%
20136.83%7.55%26.05%8.33%19.91%-2.75%18.58%-13.12%3.46%43.40%2.61%3.18%196.07%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of APLLTD.NS is 90, placing it in the top 10% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of APLLTD.NS is 9090
APLLTD.NS (Alembic Pharmaceuticals Limited)
The Sharpe Ratio Rank of APLLTD.NS is 9393Sharpe Ratio Rank
The Sortino Ratio Rank of APLLTD.NS is 9191Sortino Ratio Rank
The Omega Ratio Rank of APLLTD.NS is 8989Omega Ratio Rank
The Calmar Ratio Rank of APLLTD.NS is 8686Calmar Ratio Rank
The Martin Ratio Rank of APLLTD.NS is 9191Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alembic Pharmaceuticals Limited (APLLTD.NS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


APLLTD.NS
Sharpe ratio
The chart of Sharpe ratio for APLLTD.NS, currently valued at 1.94, compared to the broader market-2.00-1.000.001.002.003.001.94
Sortino ratio
The chart of Sortino ratio for APLLTD.NS, currently valued at 2.81, compared to the broader market-4.00-2.000.002.004.006.002.81
Omega ratio
The chart of Omega ratio for APLLTD.NS, currently valued at 1.35, compared to the broader market0.501.001.502.001.35
Calmar ratio
The chart of Calmar ratio for APLLTD.NS, currently valued at 1.27, compared to the broader market0.002.004.006.001.27
Martin ratio
The chart of Martin ratio for APLLTD.NS, currently valued at 8.63, compared to the broader market-10.000.0010.0020.008.63
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.14, compared to the broader market-2.00-1.000.001.002.003.002.14
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.04, compared to the broader market-4.00-2.000.002.004.006.003.04
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.501.001.502.001.38
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.71, compared to the broader market0.002.004.006.001.71
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.02, compared to the broader market-10.000.0010.0020.008.02

Sharpe Ratio

The current Alembic Pharmaceuticals Limited Sharpe ratio is 1.94. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Alembic Pharmaceuticals Limited with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.001.502.002.503.003.502024FebruaryMarchAprilMayJune
1.94
2.42
APLLTD.NS (Alembic Pharmaceuticals Limited)
Benchmark (^GSPC)

Dividends

Dividend History

Alembic Pharmaceuticals Limited granted a 0.90% dividend yield in the last twelve months. The annual payout for that period amounted to ₹8.00 per share.


PeriodTTM20232022202120202019201820172016201520142013
Dividend₹8.00₹8.00₹10.00₹14.00₹3.00₹5.50₹4.00₹4.00₹4.00₹3.50₹3.00₹2.50

Dividend yield

0.90%1.05%1.75%1.75%0.29%0.96%0.67%0.75%0.67%0.50%0.67%1.18%

Monthly Dividends

The table displays the monthly dividend distributions for Alembic Pharmaceuticals Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00
2023₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹8.00₹0.00₹0.00₹0.00₹0.00₹0.00₹8.00
2022₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹10.00₹0.00₹0.00₹0.00₹0.00₹10.00
2021₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹14.00₹0.00₹0.00₹0.00₹0.00₹0.00₹14.00
2020₹0.00₹0.00₹3.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.00
2019₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹5.50₹0.00₹0.00₹0.00₹0.00₹0.00₹5.50
2018₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00
2017₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00
2016₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00
2015₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.50₹0.00₹0.00₹0.00₹0.00₹0.00₹3.50
2014₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.00
2013₹2.50₹0.00₹0.00₹0.00₹0.00₹0.00₹2.50

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%0.9%
Alembic Pharmaceuticals Limited has a dividend yield of 0.90%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
20.0%40.0%60.0%80.0%100.0%120.0%25.5%
Alembic Pharmaceuticals Limited has a payout ratio of 25.53%, which is quite average when compared to the overall market. This suggests that Alembic Pharmaceuticals Limited strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-35.00%-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%2024FebruaryMarchAprilMayJune
-17.88%
-0.04%
APLLTD.NS (Alembic Pharmaceuticals Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alembic Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alembic Pharmaceuticals Limited was 57.14%, occurring on Mar 29, 2023. The portfolio has not yet recovered.

The current Alembic Pharmaceuticals Limited drawdown is 17.88%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-57.14%Dec 18, 2020566Mar 29, 2023
-45.05%Jul 17, 2015712Jun 5, 2018460Apr 24, 20201172
-27.58%Nov 9, 201137Jan 2, 201264Apr 2, 2012101
-23.65%Apr 28, 201415May 19, 201434Jul 4, 201449
-20.67%Jul 30, 201315Aug 21, 201334Oct 10, 201349

Volatility

Volatility Chart

The current Alembic Pharmaceuticals Limited volatility is 7.55%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%2024FebruaryMarchAprilMayJune
7.55%
2.19%
APLLTD.NS (Alembic Pharmaceuticals Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alembic Pharmaceuticals Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items